1. Daily Temozolomide Following Failure of Prior RT + TMZ for GBM: Update on the RESCUE Study
J. Perry, W. Mason, K. Belanger, P. Kavan, D. Fulton, J. Easaw, S. Kirby, D. MacDonald, C. Shields and J.-F. Pouliot

2. 42-year-old woman with GBM treated with daily temozolomide at first relapse on the NCIC-CTG/EORTC Trial
PD: 9 mo after RT/TMZ,
6 cycles adjuvant TMZ
CR after 4 cycles continuous TMZ 50 mg/m2

3. Temozolomide Dose-intense Rescue

4. RESCUE Study Design

5. Study Objectives

6. Main Inclusion Criteria

7. Main Exclusion Criteria

9. Demographics

10. Six-month Progression-free Survival

11. Progression-free Survival (by subgroup)

12. Non hematological Toxicity (worst grade)
*All AEs irrespective of causality incidence >2%
No Grade 4 toxicity reported at this point in time

13. Hematological Toxicity (worsened grade since baseline)

14. Baseline Hematological Abnormalities (all patients)

15. Conclusions